0001193125-26-315779 Sample Contracts

RESEARCH COLLABORATION AND LICENSE AGREEMENT DATED AS OF FEBRUARY 3, 2026 BY AND BETWEEN IAMBIC THERAPEUTICS, INC. AND TAKEDA PHARMACEUTICALS, U.S.A., INC.
Research Collaboration and License Agreement • July 24th, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York

This Research Collaboration and License Agreement (this “Agreement”), effective as of February 3, 2026 (the “Effective Date”), is entered into by and between Takeda Pharmaceuticals U.S.A., Inc., a corporation organized under the laws of the State of Delaware (“Takeda”), and Iambic Therapeutics, Inc., a Delaware corporation having a place of business at 5627 Oberlin Drive, Suite 120, San Diego, California, 92121 (“Iambic”). Takeda and Iambic are referred to individually as a “Party” and collectively as the “Parties.”

View SourceView Similar (3)
IAMBIC THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
Investors’ Rights Agreement • July 24th, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 1, 2026, by and among Iambic Therapeutics, Inc., a Delaware corporation (the “Company”), the Key Holders (as defined below), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.

View SourceView Similar (2)
Contract
Warrant Agreement • July 24th, 2026 • Iambic Therapeutics, Inc. • Biological products, (no disgnostic substances) • California

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.

View Source